HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
JANX
Janux Therapeutics, Inc.
There isn't enough reported data to score JANX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
JANX Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Unavailable |
JANX's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
JANX PE Valuation
JANX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
JANX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect JANX's losses to grow, with revenue declining. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over JANX on earnings, with more consistent year-over-year improvement.
JANX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.59 | +$0.09 |
| Q2 2026 | -$1.64 | +$0.16 |
| Q1 2026 | -$1.84 | -$0.48 |
| Q4 2025 | -$1.83 | -$0.55 |
| Q3 2025 | -$1.68 | -$0.53 |
| Q2 2025 | -$1.80 | -$0.91 |
| Q1 2025 | -$1.36 | -$0.16 |
| Q4 2024 | -$1.28 | +$0.04 |
JANX lost $1.59 per share over the past year, about the same as its loss the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over JANX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over JANX on profitability, with a higher operating margin.
JANX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.3M | -7.1% |
| Q3 2025 | $10M | +2178% |
| Q3 2024 | $439K | -83% |
| Q2 2024 | $8.9M | +742% |
| Q1 2024 | $1.3M | -39% |
| Q4 2023 | $2.5M | -13% |
| Q3 2023 | $2.5M | +39% |
| Q2 2023 | $1.1M | -55% |
JANX's revenue is growing: $9M last quarter, down 7.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -337% | +16 points |
| Q2 2026 | -309% | N/A |
| Q1 2026 | -917% | N/A |
| Q3 2025 | -353% | +7812 points |
| Q3 2024 | -8164% | -7536 points |
| Q2 2024 | -155% | +1808 points |
| Q1 2024 | -1610% | -620 points |
| Q4 2023 | -656% | -14 points |
JANX's operating margin was −337% last quarter, up 7828 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over JANX on cash generation, producing positive trailing cash flow while its opponent burns cash.
JANX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$25.2M | -$12.2M |
| Q2 2026 | $12.3M | +$36.6M |
| Q1 2026 | -$12.6M | +$4.8M |
| Q4 2025 | -$28.6M | -$11.9M |
| Q3 2025 | -$12.9M | -$10.7M |
| Q2 2025 | -$24.3M | -$14.2M |
| Q1 2025 | -$17.4M | -$2.4M |
| Q4 2024 | -$16.8M | -$6.4M |
JANX has burned cash in almost every quarter: −$54M over the past year, against −$71M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over JANX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
JANX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +153K shares |
| 1 year | +1.7% | +1.1M shares |
| 3 years | +38% | +17.4M shares |
| 5 years | +529% | +53.1M shares |
| Available history | +406% | +50.6M shares |
JANX has 63M diluted shares, up 1.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
JANX Net Leverage
JANX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
JANX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.3 | Neutral |
| Stochastic | 34.0 | Neutral |
JANX's weekly RSI is 35 (neutral) and its Stochastic is 34 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
JANX PE vs Healthcare Sector
JANX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
JANX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $16.4 | 30% below |
| 20 week MA | $16.6 | 31% below |
| 50 week MA | $15.1 | 24% below |
| 100 week MA | $22.7 | 49% below |
| 200 week MA | $24.7 | 53% below |
JANX is in a downtrend: it's below all five of its weekly moving averages, and 53% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
JANX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $25.2 | $21.4 | -15% |
| 2022 | $21.4 | $11.9 | -45% |
| 2023 | $11.9 | $10.7 | -9.5% |
| 2024 | $10.7 | $54.1 | +404% |
| 2025 | $54.1 | $14.3 | -74% |
| 2026 YTD | $14.3 | $11.5 | -19% |
JANX has the edge over HIMS on returns for 2026, with the stronger performance.